The Youth Vaping Narrative Strikes Again: A Perspective Piece Built on Assumptions Rather Than Evidence

The latest Perspective article published in PLOS Medicine by Raglan Maddox, Becky Freeman, Charlotta Pisinger and Emily Banks presents itself as a warning about the deliberate targeting of young people by the tobacco and nicotine industry. At first glance, it appears to be a serious contribution to the scientific literature, but a closer reading reveals something quite different. Rather than offering new evidence, new data, or new analysis, the article is essentially an advocacy piece that repackages long-standing ideological arguments against tobacco harm reduction while presenting them as settled scientific fact.

The article begins with a sweeping assertion that contemporary nicotine products, particularly e-cigarettes, are deliberately designed, marketed and distributed to maximise youth appeal, uptake and addiction. From the opening paragraphs, the authors argue that youth vaping is not an unintended consequence but a predictable outcome of an industry that requires new generations of nicotine users to maintain profitability. While this claim may resonate with existing tobacco control narratives, readers should recognise that the article provides little direct evidence to support such a definitive conclusion. Instead, the authors rely on inference, historical analogies and assumptions about industry motives. The conclusion appears to be established before the evidence is examined.

One of the most striking features of the article is that it is not original research. It contains no new data collection, no experiments, no surveys and no statistical analysis. It is classified as a Perspective article, meaning it is fundamentally an opinion piece. Yet throughout the paper, the authors write with a level of certainty that gives the impression their claims are supported by overwhelming empirical evidence. Readers unfamiliar with the distinction between research and commentary could easily come away believing they are reading the results of a major scientific investigation rather than a set of policy arguments supported by selectively chosen references.

The article repeatedly frames youth vaping as the inevitable outcome of products designed to attract adolescents. Flavours, colourful devices, nicotine salts, social media promotion and product aesthetics are all presented as evidence of deliberate youth targeting. However, the authors never seriously engage with an alternative explanation that has been discussed for years within tobacco control and harm reduction circles: that many of the characteristics that make vaping products appealing to adult smokers seeking an alternative to cigarettes may also make them appealing to younger people. The existence of overlap does not automatically prove intent. Yet throughout the paper, the distinction between appeal and deliberate targeting is frequently blurred.

Perhaps the most revealing section of the article is its treatment of tobacco harm reduction. The authors argue that harm reduction narratives manufacture doubt, shift responsibility onto individuals and obscure the role of industry practices in creating nicotine dependence. This portrayal is highly misleading. The scientific rationale for tobacco harm reduction did not originate from tobacco companies. It emerged from independent researchers, clinicians and public health experts who recognised a basic reality that has been understood for decades: people smoke for nicotine but suffer disease primarily because of the toxic products created by combustion. This distinction is the foundation upon which the entire concept of tobacco harm reduction rests.

Instead of engaging with this central argument, the authors largely dismiss harm reduction as a rhetorical strategy designed to protect industry interests. Such a characterisation ignores the substantial body of independent evidence demonstrating that smokers who switch completely to vaping dramatically reduce their exposure to many of the toxicants found in cigarette smoke. It also ignores the fact that respected public health authorities in several countries continue to support vaping as a smoking cessation tool because they believe the evidence supports a significant reduction in risk compared with smoking. By failing to engage meaningfully with these perspectives, the article presents a one-sided account of a debate that remains far more complex than the authors acknowledge.

A particularly glaring omission is the absence of a serious discussion about smoking itself. The paper repeatedly warns about youth vaping, nicotine dependence and product appeal, but devotes remarkably little attention to the question that should sit at the centre of any public health assessment: what impact does vaping have on smoking rates? This omission is difficult to justify given that the primary public health significance of vaping lies in its potential relationship to cigarette use. Across numerous countries, smoking rates among young people and adults have continued to decline during the same period that vaping became widespread. Whether vaping is contributing to those declines remains a matter of debate, but the issue cannot simply be ignored. By focusing almost exclusively on vaping-related risks while avoiding discussion of potential benefits, the article presents an incomplete picture of the available evidence.

The authors also rely heavily on claims about the growing evidence of vaping-related harms. Yet many of the studies cited throughout the paper are observational, making it difficult to separate the effects of vaping from the effects of prior smoking, dual use or other confounding factors. Readers are repeatedly reminded of possible risks while receiving little information about the relative risks that are central to informed public health decision-making. There is no substantial discussion of biomarker studies showing reduced toxicant exposure among people who switch from smoking to vaping. There is no meaningful engagement with evidence from smoking cessation trials. There is no exploration of why several countries continue to view vaping as a useful harm reduction strategy. Instead, the article emphasises uncertainty and potential harms while largely ignoring evidence that complicates its preferred narrative.

The discussion of illicit markets is another example of the article’s selective reasoning. The authors argue that illicit tobacco and nicotine markets emerge because of weak regulation, regulatory gaps and profit-driven distribution systems. Yet this explanation sits uneasily alongside Australia’s recent experience. Australia has implemented some of the most restrictive nicotine regulations in the developed world, and during that period, the country has witnessed an explosion in illicit tobacco sales, widespread black-market vaping, organised crime involvement and a wave of firebombings linked to the tobacco trade. These developments challenge the simplistic notion that stronger restrictions automatically reduce illicit activity. Yet the article never seriously considers the possibility that prohibitionist policies themselves can create incentives for black-market growth. Such omissions are particularly striking given that one of the article’s own cited references discusses illicit tobacco policy in Australia.

The ideological foundations of the article become increasingly apparent as it progresses. The authors repeatedly invoke concepts such as colonialism, structural disadvantage, racialisation and commercial determinants of health. Several of the references cited are papers authored by the same group of researchers and discuss topics such as resisting industry narratives, colonial harms and even frameworks for abolishing the tobacco and nicotine industry altogether. This extensive self-referencing creates the impression that the article is not simply analysing evidence but reinforcing a broader ideological framework that has already been established in previous publications. Rather than testing competing hypotheses, the paper appears designed to support conclusions that were largely predetermined.

This becomes especially clear in the final policy recommendations. The authors advocate extensive restrictions on product design, flavours, retail availability, advertising, nicotine products and industry involvement in policy discussions. They call for a precautionary approach that places the burden of proving safety entirely on manufacturers. The difficulty with this approach is that it effectively creates a standard that no nicotine product could ever satisfy. Public health policy is normally guided by relative risk, asking whether one option is safer than another, not whether a product is completely devoid of risk. The key question is whether vaping presents substantially lower risks than smoking. Yet that comparison, arguably the most important one of all, receives remarkably little attention throughout the article.

The result is a paper that focuses intensely on the dangers of vaping while giving little consideration to the consequences of discouraging smokers from switching away from cigarettes. In practice, this creates a standard that lower-risk nicotine products can never satisfy, while the far greater risks posed by combustible tobacco receive comparatively little attention. The irony is difficult to ignore. A paper ostensibly concerned with reducing harm spends much of its time attacking one of the few innovations that has successfully helped millions of smokers move away from smoking.

Ultimately, this article tells readers far more about the worldview of its authors than it does about the complex realities of nicotine use, smoking cessation and tobacco harm reduction. It is not a balanced assessment of evidence but an advocacy document built upon a particular philosophy of tobacco control. Evidence that supports this philosophy is highlighted, while evidence that challenges it is minimised or ignored. The authors ask readers to view vaping through a single lens: as a deliberate system of youth addiction engineered by industry. Yet public health policy is rarely improved by viewing complex issues through only one lens. If policymakers accept this narrative uncritically, they risk repeating the same mistake that has characterised much of the vaping debate over the past decade: becoming so focused on the potential harms of vaping that they lose sight of the far greater harms caused by smoking.